#SynKIR-310
LightNews LightNews
stocktitan.net
#CYRX Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs

https://www.stocktitan.net/news/CYRX/cryoport-s-integri-cell-cryopreservation-services-selected-by-q9kjkr3ibnc8.html
Cryoport lands Verismo for clinical cell therapy cryopreservation
Verismo's SynKIR-110 and SynKIR-310 are in Phase 1 trials; Cryoport says IntegriCell will support process development, transfer and cryopreservation.
www.stocktitan.net
June 25, 2026 at 12:00 PM
newsen.bsky.social
Verismo Therapeutics Reveals Promising Preclinical Findings for SynKIR™-310 KIR-CAR in B Cell Malignancies#USA#San_Diego#Verismo_Therapeutics#SynKIR™-310#KIR-CAR
Verismo Therapeutics Reveals Promising Preclinical Findings for SynKIR™-310 KIR-CAR in B Cell Malignancies
Verismo Therapeutics showcases new preclinical data for SynKIR™-310 KIR-CAR that indicates enhanced anti-tumor activity and potential in treating B cell malignancies.
third-news.com
April 21, 2026 at 4:22 PM
newsen.bsky.social
Verismo Therapeutics Unveils Groundbreaking KIR-CAR Data at AACR Annual Meeting 2026#USA#San_Diego#Immuno-Oncology#Verismo_Therapeutics#SynKIR
Verismo Therapeutics Unveils Groundbreaking KIR-CAR Data at AACR Annual Meeting 2026
At the AACR Annual Meeting 2026, Verismo Therapeutics will present promising Phase 1 data on its innovative KIR-CAR therapies, SynKIR™-110 and SynKIR™-310, highlighting advancements in immunotherapy for various cancers.
third-news.com
March 17, 2026 at 11:07 PM
newsen.bsky.social
Verismo Therapeutics Reveals Groundbreaking Data on SynKIR™-310 CAR T Therapy at ASH 2025#USA#Philadelphia#CAR_T_Therapy#Verismo_Therapeutics#SynKIR-310
Verismo Therapeutics Reveals Groundbreaking Data on SynKIR™-310 CAR T Therapy at ASH 2025
Verismo Therapeutics presented new preclinical findings on SynKIR™-310, showcasing enhanced tumor control and reduced cytokine release compared to traditional CAR-T therapies.
third-news.com
December 9, 2025 at 1:51 PM
newsen.bsky.social
Verismo Therapeutics Initiates Phase 1 Trial of SynKIR™-310 for Advanced Lymphomas#United_States#Denver#Verismo_Therapeutics#SynKIR-310#CELESTIAL-301
Verismo Therapeutics Initiates Phase 1 Trial of SynKIR™-310 for Advanced Lymphomas
Verismo Therapeutics has announced the start of its Phase 1 CELESTIAL-301 trial for SynKIR™-310, targeting relapsed B cell Non-Hodgkin Lymphomas. The trial aims to offer new treatment options for patients facing these challenging cancers.
third-news.com
January 10, 2025 at 1:32 PM
newsen.bsky.social
Verismo Therapeutics Partners with IFLI to Boost SynKIR™-310 for Follicular Lymphoma Treatment#USA#Philadelphia#IFLI#Verismo_Therapeutics#SynKIR™-310
Verismo Therapeutics Partners with IFLI to Boost SynKIR™-310 for Follicular Lymphoma Treatment
Verismo Therapeutics announces a strategic investment partnership with IFLI to enhance development of SynKIR™-310 aimed at treating follicular lymphoma.
third-news.com
January 7, 2025 at 1:37 PM
l2plabs.bsky.social
Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX)...
dlvr.it
June 25, 2026 at 12:03 PM
l2plabs.bsky.social
Verismo Therapeutics Shares Positive Preclinical Data at ASH 2025 Comparing SynKIR™-310 With Conventional CAR-T
SynKIR™-310 achieved greater tumor control at lower doses with reduced cytokines in vivo, compared to CD19-targeted CAR T cells analogous to tisagenlecleucel. PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR...
dlvr.it
December 9, 2025 at 1:01 PM
l2plabs.bsky.social
Verismo Therapeutics Treats First Follicular Lymphoma Patient in CELESTIAL-301 Trial, Strengthening Collaboration with IFLI
PHILADELPHIA, Oct. 2, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has treated the first patient with follicular lymphoma (FL) in its CELESTIAL-301 Phase 1 clinical trial of SynKIR™-310....
dlvr.it
October 2, 2025 at 12:05 PM
l2plabs.bsky.social
Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma
Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging IFLI's…
dlvr.it
January 7, 2025 at 1:10 PM